Objectives

Clinical objectives

to further develop and validate a comprehensive prognostic model which allows to optimise individual treatment choices
to develop and validate in particular a prognostic model for treatment with tyrosine kinase inhibitors
to evaluate the sequelae of discontinuation of treatment after major or complete molecular response (MMR/CMR)
to evaluate the mechanisms and sequelae of tyrosine kinase inhibitors failure
to assess the type, frequency and sequelae of other cytogenetic abnormalities
to assess the type, frequency and sequelae of BCR-ABL point mutations
to evaluate type, frequency and duration of complete molecular response
to evaluate survival outcomes in patients treated with tyrosine kinase inhibitors

to collect baseline-, treatment- and outcome data of representative samples of CML patients of all European countries
to estimate the incidence of CML stratified for age, sex and region
to evaluate the medical management of CML-patients using the ELN recommendations (JCO 2009) as reference

Provide a clear epidemiological picture of CML and patient treatment and outcomes and to identify demographic and geographic variations
Promote understanding of how patients are treated in real life — outside of the trial setting — and their outcomes
Evaluate quality-controlled outcomes and implementation of ELN recommendations
Develop a comprehensive prognostic model to optimize treatment
Create data of high scientific value for publication

Created by: Hellenbrecht , generated 2007/12/19 , last changed: 2011/05/24